Review Article

You have full text access to this OnlineOpen article

Adjuvant therapy for pancreatic cancer

A review

  1. Dan S. Zuckerman MD,
  2. David P. Ryan MD†,*

Article first published online: 29 NOV 2007

DOI: 10.1002/cncr.23174

Issue

Cancer

Cancer

Volume 112, Issue 2, pages 243–249, 15 January 2008

Additional Information

How to Cite

Zuckerman, D. S. and Ryan, D. P. (2008), Adjuvant therapy for pancreatic cancer. Cancer, 112: 243–249. doi: 10.1002/cncr.23174

Author Information

  1. Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

  1. †

    Fax: (617) 643-1894

*Division of Medical Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey 7, Boston, MA 02114

Publication History

  1. Issue published online: 4 JAN 2008
  2. Article first published online: 29 NOV 2007
  3. Manuscript Accepted: 25 JUN 2007
  4. Manuscript Received: 31 MAY 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (98K)

REFERENCES

  • 1
    Jemal A,Siegel R,Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56: 106–130.
    Direct Link:
  • 2
    Bakkevold KE,Arnesjo B,Dahl O,Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater–results of a controlled, prospective, randomised multicentre study. Eur J Cancer. 1993; 29A: 698–703.
  • 3
    Geer RJ,Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993; 165: 68–72; discussion 72–73.
  • 4
    Trede M,Schwall G,Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg. 1990; 211: 447–458.
  • 5
    Tsao JI,Rossi RL,Lowell JA. Pylorus-preserving pancreatoduodenectomy. is it an adequate cancer operation? Arch Surg. 1994; 129: 405–412.
  • 6
    Yeo CJ,Cameron JL,Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg. 1995; 221: 721–731; discussion 731–733.
  • 7
    Lim JE,Chien MW,Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003; 237: 74–85.
  • 8
    Nishiyama Y,Yamamoto Y,Yokoe K, et al. Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer. Ann Nucl Med. 2005; 19: 491–497.
  • 9
    Begg CB,Cramer LD,Hoskins WJ,Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA. 1998; 280: 1747–1751.
  • 10
    Birkmeyer JD,Stukel TA,Siewers AE,Goodney PP,Wennberg DE,Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003; 349: 2117–2127.
  • 11
    Hollenbeck BK,Dunn RL,Miller DC,Daignault S,Taub DA,Wei JT. Volume-based referral for cancer surgery: informing the debate. J Clin Oncol. 2007; 25: 91–96.
  • 12
    Griffin JF,Smalley SR,Jewell W, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer. 1990; 66: 56–61.
    Direct Link:
  • 13
    Sperti C,Pasquali C,Piccoli A,Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg. 1997; 21: 195–200.
  • 14
    Tepper J,Nardi G,Sutt H. Carcinoma of the pancreas: review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Cancer. 1976; 37: 1519–1524.
    Direct Link:
  • 15
    Westerdahl J,Andren-Sandberg A,Ihse I. Recurrence of exocrine pancreatic cancer–local or hepatic? Hepatogastroenterology. 1993; 40: 384–387.
  • 16
    Moertel CG,Childs DSJr,Reitemeier RJ,Colby MYJr,Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 1969; 2: 865–867.
  • 17
    Moertel CG,Frytak S,Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer. 1981; 48: 1705–1710.
    Direct Link:
  • 18
    Kalser MH,Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985; 120: 899–903.
  • 19
    Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer. 1987; 59: 2006–2010.
    Direct Link:
  • 20
    Klinkenbijl JH,Jeekel J,Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999; 230: 776–782; discussion 782–784.
  • 21
    Neoptolemos JP,Dunn JA,Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001; 358: 1576–1585.
  • 22
    Neoptolemos JP,Stocken DD,Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004; 350: 1200–1210.
  • 23
    Stocken DD,Buchler MW,Dervenis C, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer. 2005; 92: 1372–1381.
  • 24
    Dobelbower RR,Merrick HW,Khuder S,Battle JA,Herron LM,Pawlicki T. Adjuvant radiation therapy for pancreatic cancer: a 15-year experience. Int J Radiat Oncol Biol Phys. 1997; 39: 31–37.
  • 25
    Farrell TJ,Barbot DJ,Rosato FE. Pancreatic resection combined with intraoperative radiation therapy for pancreatic cancer. Ann Surg. 1997; 226: 66–69.
  • 26
    Hiraoka T,Uchino R,Kanemitsu K, et al. Combination of intraoperative radiation with resection of cancer of the pancreas. Int J Pancreatol. 1990; 7(1-3): 201–207.
  • 27
    Hishinuma S,Ogata Y,Matsui J,Ozawa I. Results of surgery and adjuvant radiotherapy for pancreatic cancer. J Hepatobiliary Pancreat Surg. 1998; 5: 143–150.
  • 28
    Hosotani R,Kogire M,Arii S,Nishimura Y,Hiraoka M,Imamura M. Results of pancreatectomy with radiation therapy for pancreatic cancer. Hepatogastroenterology. 1997; 44: 1528–1535.
  • 29
    Picozzi VJ,Kozarek RA,Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg. 2003; 185: 476–480.
  • 30
    Sindelar WF,Kinsella TJ. Studies of intraoperative radiotherapy in carcinoma of the pancreas. Ann Oncol. 1999; 10( suppl 4): 226–230.
  • 31
    Takada T,Amano H,Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002; 95: 1685–1695.
    Direct Link:
  • 32
    Tuckson WB,Goldson AL,Ashayeri E,Halyard-Richardson M,DeWitty RL,Leffall LDJr. Intraoperative radiotherapy for patients with carcinoma of the pancreas. The Howard University Hospital experience, 1978–1986. Ann Surg. 1988; 207: 648–654.
  • 33
    Regine WF,Winter KW,Abrams R, et al. RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. Proc Am Soc Clin. 2006; 24. Abstract 4007.
  • 34
    Demols A,Peeters M,Polus M, et al. Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: a multicenter Belgian Phase II study. Int J Radiat Oncol Biol Phys. 2005; 62: 1351–1356.
  • 35
    Wilkowski R,Thoma M,Duhmke E,Rau HG,Heinemann V. Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma. Int J Radiat Oncol Biol Phys. 2004; 58: 768–772.
  • 36
    Oettle H,Post S,Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297: 267–277.
  • 37
    Spitz FR,Abbruzzese JL,Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 1997; 15: 928–937.
  • 38
    Moutardier V,Magnin V,Turrini O, et al. Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2004; 60: 437–443.
  • 39
    Evans DB,Rich TA,Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992; 127: 1335–1339.
  • 40
    Hoffman JP,Lipsitz S,Pisansky T,Weese JL,Solin L,Benson AB3rd. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1998; 16: 317–323.
  • 41
    Ishikawa O,Ohhigashi H,Teshima T, et al. Clinical and histopathological appraisal of preoperative irradiation for adenocarcinoma of the pancreatoduodenal region. J Surg Oncol. 1989; 40: 143–151.
    Direct Link:
  • 42
    Jessup JM,Steele GJr,Mayer RJ, et al. Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg. 1993; 128: 559–564.
  • 43
    Kopelson G. Curative surgery for adenocarcinoma of the pancreas/ampulla of Vater: the role of adjuvant pre or postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 1983; 9: 911–915.
  • 44
    Pilepich MV,Miller HH. Preoperative irradiation in carcinoma of the pancreas. Cancer. 1980; 46: 1945–199.
    Direct Link:
  • 45
    Breslin TM,Hess KR,Harbison DB, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol. 2001; 8: 123–132.
  • 46
    Pisters PW,Abbruzzese JL,Janjan NA, et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol. 1998; 16: 3843–3850.
  • 47
    Pisters PW,Wolff RA,Janjan NA, et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol. 2002; 20: 2537–2544.
  • 48
    Staley CA,Lee JE,Cleary KR, et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg. 1996; 171: 118–124; discussion 124–125.
  • 49
    Talamonti MS,Small WJr,Mulcahy MF, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006; 13: 150–158.
  • 50
    Varadhachary GREvans DB,Crane CH, et al. Interim results of preoperative gemcitabine (GEM) plus cisplatin followed by rapid fractionation chemoradiation for resectable pancreatic adenocarcinoma. J Clin Oncol. 2006; 24. Abstract 4037.
  • 51
    Wolff RA,Evans DB,Crane CH, et al. Initial results of preoperative gemcitabine (GEM)-based chemoradiation for resectable pancreatic adenocarcinoma. Proc Am Soc Clin Oncol. 2002; 21. Abstract 516.
View Full Article (HTML) Get PDF (98K)